INTRODUCTION
Over the last 20 years, treatment paradigms for stage I-III breast cancer have evolved, and among many other advances, the use of adjuvant chemotherapy has become a routine consideration.
1,2 Nevertheless, treatment decisions in the adjuvant setting can be particularly complex, and the benefits and risks of therapy can vary dramatically between different individuals given individual disease and therapy risks. For example, adjuvant chemotherapy reduces the risk of breast cancer recurrence for patients with stage I-III breast cancer by an average of 30%. For a patient who is younger than 50 years of age with node-positive disease, this yields at least a 10% absolute survival benefit and disease-free survival gain of almost 1 year. 2, 3 In contrast, for a 50-to 69-year-old patient with node-negative breast cancer, the absolute survival benefit will be in the 2% range, and the disease-free survival gain will be approximately 6 months. 2, 3 The probability of severe toxicity by chemotherapy also varies among individual patients. For example, older patients have a greater incidence of congestive heart failure associated with anthracycline treatment when compared with younger patients, and clinical factors such as age, baseline fatigue, depression, and functional status are associated with a higher risk of chemotherapy-related cognitive decline. [4] [5] [6] There is an increasing recognition that patients' preferences should play an important role in medical treatment decisions, yet very few data exist regarding patients' preferences for modern adjuvant chemotherapy. 7 Previous studies have suggested that most patients with early breast cancer were willing to receive 6 months of adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy for modest survival benefits (most women would have accepted a 3-to 6-month extension of life), even when acknowledging potential adverse effects. 3, [8] [9] [10] In addition, it has been suggested that physicians frequently do not necessarily share patients' views, sometimes being less likely to recommend chemotherapy for a small chance of benefit. 9, 11 With patients playing a more active role in their care as well as novel therapies having different toxicities, preferences could have changed over time. To determine early-stage breast cancer patients' views on the survival benefit needed to justify 6 months of chemotherapy, we surveyed patients in the Eastern Cooperative Oncology Group Protocol 5103 (E5103), a phase 3 trial in which all patients were randomized to receive at least a current standard adjuvant breast cancer chemotherapy regimen (doxorubicin, cyclophosphamide and paclitaxel [ACT]) with either placebo or one of two arms that combined ACT chemotherapy with two different durations of bevacizumab. We also examined physicians' preferences regarding the survival benefit needed to justify 6 months of chemotherapy.
PATIENTS AND METHODS

Data Source
All patients enrolled in E5103 between January 1, 2010, and June 8, 2010, were included in the decision making/ quality of life component of this study. Institutional review board approval for the clinical trial was received through participating sites for study participation, and written informed consent was obtained from participants before study enrollment.
Surveys
Serial surveys were administered at baseline and 18 months after enrollment to examine the potential longterm effects of the treatments on patients' quality of life. The 18-month survey included pilot-tested questions that focused on preferences for receiving chemotherapy; these questions were the basis of this study. In addition, a parallel physicians' survey was sent to doctors who enrolled patients in E5103. Six questions asked whether 6 months of chemotherapy would be worthwhile for a 1-, 2-, 6-, 9-, 12-, and 24-month survival benefit, with 3 possible answers for each question: 1) yes, definitely worthwhile; 2) yes, maybe worthwhile; and 3) no, not worthwhile. Using life expectancy gain is a well-established method for eliciting preferences for chemotherapy. 9, 10, 12 
Data Collection
Patients' surveys were completed by telephone interview by centralized staff. Patients were mailed a copy of the survey 2 weeks before the phone interview. Most patients completed the survey before the interview, and the interview served to collect the answers. If not completed ahead of time, or if the patient did not have a copy, survey questions were read aloud. Patients could ask questions about the survey at any point and were allowed to skip survey questions they were not comfortable answering.
Physicians were e-mailed a link to a brief web-based survey of their background and practice, and the preference items were modified as recommendations for a patient.
Statistical Methods
The primary outcomes of interest were the proportion of patients/physicians who were willing to consider chemotherapy (yes [definitely worthwhile or maybe worthwhile] vs no [not worthwhile]) for 2 or less months of survival benefit from receiving 6 months of chemotherapy and those who did not consider chemotherapy for 9 months of survival benefit from receiving 6 months of chemotherapy.
A Fisher's exact test for categorical variables (Wilcoxon rank sum test for ordered variables) was used to assess for univariate associations between willingness to consider 6 months of chemotherapy (no, yes) for 2 months of survival benefit and for 9 months of survival benefit for the covariates listed below. Using these same covariates from the patient analysis, multivariate logistic regression was used to assess for predictors of willingness to consider 6 months of chemotherapy (yes vs no for 2 months of survival and no vs yes for 9 months of survival). For physicians' preferences, no multivariate logistic models were performed due to small sample sizes. Covariates of interest in the patient analysis included age, race, marital status, education level, hormone receptor status, grade, tumor size, nodal status, surgery, toxicity experienced (grade 3, 4, or 5 adverse events defined by the Common Terminology Criteria for Adverse Events version 4.0 13 ), and treatment arm. Covariates of interest in the physician analysis included age, sex, race, years in profession, years in current practice, practice size, practice setting, number of new patients seen per month, number of new breast cancer patients seen per month, and number of patients physicians enroll on clinical trials per month. Two-sided P values less than .05 were considered statistically significant.
RESULTS
During the quality of life enrollment period, 571 patients started the protocol therapy, and 519 patients who had not withdrawn at a time point earlier than 18 months were contacted; 465 patients answered at least 1 question Original Article across all of the 18-month surveys, and 456 patients answered the 2 primary questions regarding willingness to receive chemotherapy for 2 and 9 months of survival benefit (an 87.8% response rate). Of the 1123 physicians who registered at least 1 patient on E5103, 179 answered at least 1 question in this entire survey and 175 physicians answered the 2 primary questions regarding willingness to recommend chemotherapy (16% response rate) (Fig. 1) .
The median patient age was 51.5 years (range, 25-76 years), and most patients were white (86%). The majority of patients were married or had a partner (72%), and 44% of patients had at least a college degree. The majority had hormone receptor-positive disease (65%) and had nodal involvement (72%) ( Table 1) .
The median physician age was 50 years (range, 35-70 years), 64% were males, and the vast majority were white (83%). The median number of years in the profession was 16.5 (range, 3-38), the majority were in academia (62%), and most of them saw 16 or more new patients per month (56%) and 5 or more new breast cancer patients per month (79%) ( Table 2) .
Trade-offs of Survival Benefit Needed to Consider Chemotherapy
The proportion of patients willing to receive chemotherapy in exchange for survival benefit varied according to the magnitude of the survival benefit considered; nevertheless, we found considerable variation in patients' preferences, particularly for modest survival benefits. A substantial minority of patients (24%) would consider 6 months of chemotherapy definitely worthwhile for a 1-month survival benefit, 18% would possibly consider it, and 56% would not. For 2 months of benefit, 57% would consider chemotherapy (34% yes, definitely worthwhile; 23% yes, maybe worthwhile) and 42% would not.
Approximately half of patients considered 6 months of chemotherapy definitely worthwhile and 34% would possibly consider it for 9 months benefit. The percentage considering chemotherapy definitely worthwhile increased with greater benefit but did not reach 100%, even with 24 months survival benefit.
Overall (n 5 456), fewer patients responded "no" to 9 months of benefit (12% [53/456]) versus "no" to 2 months of benefit (42% [193/456] ).
Physicians' preferences also varied, particularly for modest survival benefits, but this variation was less pronounced compared with that observed among patients. Physicians were less likely to accept chemotherapy for a small chance of benefit (eg, 34% of patients vs 5% of physicians would definitely consider chemotherapy worthwhile for 2 months of benefit). For greater benefit, patients' and physicians' choices were similar (84% of patients vs 92% of physicians would definitely consider chemotherapy worthwhile for 24 months benefit) (Fig. 2) .
Factors Associated With Trade-offs
Patient preferences
A lower proportion of white patients were willing to consider 6 months of chemotherapy for 2 months of survival benefit when compared with patients of other race (54% [213/393] vs 79% [50/63], respectively; P < .01). Thirteen percent (52/393) of white patients were not willing to consider chemotherapy for 9 months of benefit versus 2% (1/63) of patients of other race (P < .01).
In addition, more educated (college or higher) patients were also less likely to consider chemotherapy for 2 months of benefit when compared with less educated patients (less than college) (51% [97/190] vs. 62% [148/ 239], respectively; P 5 .02), but education level was not associated with willingness to not consider 9 or more months of benefit (Table 1) . These same covariates remained significant on multivariate logistic regression to assess association with 2-and 9-month survival benefit (data not shown).
In this study, we did not find substantial trade-off differences for willingness to consider chemotherapy for 2 months of benefit or to not consider it for 9 months of benefit by tumor features, treatment characteristics (type of surgery, ACT with or without bevacizumab), or toxicity experienced on study (grade 3, 4, or 5 adverse events).
Physician preferences
A lower proportion of physicians who see more than 20 new patients per month would recommend chemotherapy for 2 months of survival benefit when compared with physicians who see fewer new patients per month (P < .01). A lower proportion of physicians with 10.5 or more years in their current practice said that they would recommend chemotherapy for 2 months of benefit when compared with physicians with fewer than 10. No differences in other features (age, years in profession, practice size, new breast cancer patients per month, patients on clinical trials per month) were found among physicians willing to recommend 6 months of chemotherapy for 2 months of benefit. Because the vast majority of physicians would recommend chemotherapy for 9 months of benefit, we had limited ability to find associations between those who would not recommend it versus those who would recommend it for 9 months of benefit.
DISCUSSION
Over the last decade, increasing attention to consumer satisfaction in medicine in addition to patients' desires to actively participate in their medical decision process has promoted the consensus that a "quality decision in medicine is the one that takes into account patients' preferences and in which patients are informed and receive treatments to match their goals." 7, 14 Involving patients in treatment decisions is increasingly recognized as "the right to autonomy." 7 In a time of treatment guidelines and pathways, patients vary in the value they place on potential benefits of a toxic treatment such as chemotherapy. 10 Our study, which demonstrated such heterogeneity in patient preferences, focused on a population of patients who enrolled in a clinical trial and who were treated with a modern chemotherapy regimen (ACT) and replicates studies performed 20 years ago among breast cancer survivors mainly treated with cyclophosphamide, methotrexate, and 5-fluorouracil. Our findings are consistent with the data from these previous studies, showing that variation in patient preferences persists even with changing times and toxicities, and reemphasizing the need of involving patients in the medical decision process. Several points can be taken from our data in support of this assessment.
First, our findings suggest that for women for whom the benefit of chemotherapy may be modest and questionable, there is substantial variability in patient preferences. Many women would be willing to consider 6 months of chemotherapy for 2 months of benefit (57%), but a substantial minority would not (42%). Older studies had similar results. 3, [8] [9] [10] For example, in 1998, Lindley et al 9 reported a study in which they evaluated 239 breast cancer patients with no evidence of recurrence 2-5 years after start of adjuvant treatment and found that 47% of patients were willing to receive 6 months of chemotherapy for an additional 3 months of life. 9 Similarly, Ravdin et al 10 reported that among 318 breast cancer survivors, more than 40% of women who had received adjuvant chemotherapy for breast cancer would accept adjuvant chemotherapy in exchange for 3 months of life.
Second, consistent with previous studies, 3, 9, 10, 14, 15 we found that although patient preferences for chemotherapy increase as benefits increase, a small minority (2%) of patients would not want to receive chemotherapy even for a 2-year survival benefit. Third, our data also show that patient and physician preferences are not concordant for modest survival benefits. This finding has been observed in previous oncology and nononcology studies, 9, 11, [16] [17] [18] [19] [20] which often report that the degrees of benefit that physicians feel are not significant are different from those reported by patients. 9, 11, [16] [17] [18] [19] [20] Finally, our study suggests that some of the variability in patient preferences may be associated with social and cultural features; race and education level were significantly associated with patients' choices and may generate insight into what factors drive patient preferences.
Although this study was able to successfully capture patient preferences in a large cohort of subjects (87.8% response rate) treated with modern adjuvant chemotherapy, we acknowledge several limitations. First, patients who participated in this survey were sampled from a large clinical trial; as such, there may be concerns about the generalizability of our results. Furthermore, our patients did not represent the typical patient with early breast cancer handling chemotherapy decisions. Our population was younger (median age, 51.5 years) and better educated (44% had at least a college education). 7, 21 In addition, all patients had high-risk disease, for which there is usually a strong indication for anthracycline-taxane-based chemotherapy (and all of the patients in our study received chemotherapy). 7, 21 It is also possible that patients who have chosen to have chemotherapy (and in addition to participate on a trial) may overestimate the value of chemotherapy when compared with those who choose not to take it (and not to participate on a trial). 7, 21 It is also likely that different durations of chemotherapy (eg, shorter regimens such as 3 months) could impact willingness to receive chemotherapy. Second, previous experiences suggest that patients' views change over time and are influenced by their past. When capturing patients' experiences regarding chemotherapy after they have received it, patients may be likely to be less apprehensive about chemotherapy-related toxicity and more likely to want to believe that the previous decision was the correct one, both of which may have influenced their response in the surveys. 9, 10 Third, the way in which a question is framed may influence the answer. Lindley et al 9 and Slevin et al 14 examined both the life expectancy gain and increase in survival percentage that would make 6 months of chemotherapy worthwhile. In both studies, the same patients that accepted just 1% improvement in cure rate sometimes needed a benefit of 12 months in terms of survival prolongation. Our cognitive testing similarly suggested that patients had widely varying interpretations of, for example, a 2% or 10% survival increase, whereas their interpretation of a 6-or 12-month extension of life was fairly consistent. As a result, we selected life expectancy gained as the approach to elicit preferences in this study. It should be noted that by choosing this approach, we are not advocating months of life expectancy gained as a way to communicate risk, and are instead simply highlighting the variability in patient preferences. Fourth, our study did not capture all factors associated with patient preferences (eg, we did not have the ability to evaluate the contribution of patient-physician interaction). Fifth, the physicians' survey response rate was low; therefore, these data can be read only as illustrative. Finally, although our results suggest aggregate differences in patient and physicians choices, we did not conduct individual analyses to understand how preferences of each specific patient were incongruent with provider choice or how this impacted patient distress.
Previous studies have suggested that patient preferences are not being taken into consideration when chemotherapy decisions are being made even if it is widely accepted that a shared patient-physician medical decision making model is ideal.
14 In this setting, our findings have important implications. The decision about a modern type of chemotherapy is "preference sensitive," and therefore although evidence and clinical guidelines are essential, eliciting and understanding his or her comfort level with the benefits and risks of chemotherapy remains critical to determine the best approach to treatment. There is a need for some flexibility for clinicians to incorporate patient preferences when selecting treatments. 7, 21 Developing methods of explaining treatment decisions to patients that promote better patient-physician communication (eg, Adjuvant! Online) and obtain patient preferences constitutes a high priority of research. 7, 9, 22 As demonstrated in this study, this is particularly relevant in situations where the benefits of chemotherapy are modest, but may also be meaningful for those for which the benefits are substantial.
